News - Jasper Therapeutics

News Center

September 20, 2021

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members

September 08, 2021

Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes

June 21, 2021

Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease

June 14, 2021

Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant

June 1, 2021

Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting

May 26, 2021

Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease

May 19, 2021

Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

May 7, 2021

Jasper Therapeutics SPAC Definitive Business Combination Webcast

May 6, 2021

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation

February 11, 2021

Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease

February 8, 2021

Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

January 13, 2021

Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID

January 11, 2021

Jasper Therapeutics to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

December 7, 2020

Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID Undergoing Hematopoietic Cell Transplantation

September 22, 2020

Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent for Patients with Myelodysplastic Syndromes/Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

August 12, 2020

Jasper Therapeutics Strengthens Management Team with Appointment of Biopharma Industry Executive Kevin N. Heller, M.D., as Executive Vice President, Research and Development

January 9, 2020

Jasper Therapeutics Expands Series A Bringing Total Corporate Funding to More Than $50 Million

December 9, 2019

Jasper Therapeutics Announces Upcoming Data on JSP191 at 61st American Society of Hematology

December 6, 2019

Jasper Therapeutics Launches with $35 Million Series A Financing

Top

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Others